Pharmacokinetics of cannabidiol administered by 3 delivery methods at 2 different dosages to healthy dogs

Lisa R. Bartner, Stephanie McGrath, Sangeeta Rao, Linda K. Hyatt, Luke Anthony Wittenburg

Research output: Contribution to journalArticle

10 Scopus citations

Abstract

The purpose of this study was to determine the pharmacokinetics of cannabidiol (CBD) in healthy dogs. Thirty, healthy research dogs were assigned to receive 1 of 3 formulations (oral microencapsulated oil beads, oral CBD-infused oil, or CBD-infused transdermal cream), at a dose of 75 mg or 150 mg q12h for 6 wk. Serial cannabidiol plasma concentrations were measured over the first 12 h and repeated at 2, 4, and 6 wk. Higher systemic exposures were observed with the oral CBD-infused oil formulation and the half-life after a 75-mg and 150-mg dose was 199.7 ± 55.9 and 127.5 ± 32.2 min, respectively. Exposure is dose-proportional and the oral CBD-infused oil provides the most favorable pharmacokinetic profile.

Original languageEnglish (US)
Pages (from-to)178-183
Number of pages6
JournalCanadian Journal of Veterinary Research
Volume82
Issue number3
StatePublished - Jul 1 2018

ASJC Scopus subject areas

  • veterinary(all)

Fingerprint Dive into the research topics of 'Pharmacokinetics of cannabidiol administered by 3 delivery methods at 2 different dosages to healthy dogs'. Together they form a unique fingerprint.

  • Cite this